Goldman Sachs
KALV

Goldman Sachs’s KalVista Pharmaceuticals KALV Stock Holding History

Goldman Sachs’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-243,600
Closed -$2.98M – 5730
2023
Q4 		$2.98M Buy
+243,600
New +$2.22M ﹤0.01% 3601

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's KALV Position: Q1 2026 in Review

Goldman Sachs reduced its KalVista Pharmaceuticals (KALV) stake by 1.3% in Q1 2026, selling an estimated $177K and leaving 824,293 shares worth $16.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Goldman Sachs first reported a position in KALV in Q2 2015 and has held it in 34 quarters since. The position peaked at $21.9M in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Goldman Sachs held 824,293 shares of KalVista Pharmaceuticals worth $16.6M as of Q1 2026.
  • Goldman Sachs sold 11,011 KalVista Pharmaceuticals shares in Q1 2026, an estimated $177K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2614 holding.
  • Goldman Sachs first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 34 quarters since.
  • Goldman Sachs's KalVista Pharmaceuticals position peaked at $21.9M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.